/
Oncology
Metastatic Breast Cancer
54
Pipeline Programs↗
74
Active Trials↗
28
Companies Involved↗
Metastatic Breast Cancer is a moderately active landscape with 54 programs across 28 companies. The most active players are Roche, Merck & Co., Boehringer Ingelheim. 19 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical19
Phase 14
Phase 212
Phase 319
Approved
No programs
Analysis
Modality Breakdown
74%
Small molecule
37 of 50 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 50 classified programs, each share of the total. Modality classified for 93% of 54 pipeline programs.
Analysis
Trial Status
93
clinical trials
Recruiting42 · 45%
Active, not recruiting25 · 27%
Completed13 · 14%
Not yet recruiting7 · 8%
Terminated5 · 5%
Available1 · 1%
Clinical Trials
Trial Activity
93 trials
Page 1 of 7
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)